Pioneering combo therapy trial launches for aggressive blood cancer
NCT ID NCT05495464
Summary
This early-phase study is testing a three-step treatment for people newly diagnosed with a high-risk form of mantle cell lymphoma, a type of blood cancer. First, patients receive two drugs (acalabrutinib and rituximab), followed by an infusion of their own genetically modified immune cells (CAR T-cell therapy). The main goal is to see if this sequence is safe and can effectively control the disease in this specific high-risk group.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.